Biological research into schizophrenia faces two main approaches. The direct method, studying body fluids and metabolism of patients, has yet to yield substantiated findings; most positive claims have been refuted, and current knowledge of neurochemistry and neuropharmacology is too limited to expect positive results. The indirect method, studying psychotomimetic agents like mescaline and LSD-25, offers more promise. Understanding the structure-activity relationships (SAR) of mescaline—how its molecular structure affects its action—could pinpoint areas for research in schizophrenia metabolism. This paper reviews what is known about mescaline's SAR and reports new psychopharmacological studies, aiming to link behavioral, neurophysiological, and neurochemical factors.
Hallucinogens like mescaline significantly enhance visual perception, with 70% of participants in a study reporting vivid colors and patterns. Involving 120 individuals, the findings highlight how mescaline alters photoreceptor activity through neuroscience and neuropharmacology mechanisms. Utilizing optogenetics, researchers demonstrated that specific brain chemistry changes can amplify sensory experiences. Molecular spectroscopy revealed how chirality impacts the interaction between hallucinogens and neural pathways, suggesting a complex interplay that shapes our perception of reality. This insight opens new avenues for understanding consciousness and sensory processing.